Your browser is not currently configured to accept cookies from this website.
This means that the site will not run as smoothly/quickly as possible and could result in certain functionality not working as designed. Endocrine Society Statement of Principle Scientific Statements Clinical Practice Guidelines Continuing Medical Education: Clinical Practice Guidelines and Translational Endocrinology & Metabolism Position Statements Click the title above to read Wiley’s book proposal guidelines.
Therapeutic drug monitoring (TDM) may help to minimize toxicity while adequate drug exposure is maintained.
Conventional plasma sampling and monitoring might be hindered in many parts of the world by logistical problems that may be solved by dried blood spot (DBS) sampling.
The aim of this study was to develop and validate a novel method for TDM of linezolid in MDR-TB patients using DBS sampling.
Plasma, venous DBS, and capillary DBS specimens were obtained simultaneously from eight patients receiving linezolid.
A DBS sampling method was developed and clinically validated by comparing DBS with plasma results using Passing-Bablok regression and Bland-Altman analysis.
This study showed that DBS analysis was reproducible and robust.
Accuracy and between- and within-day precision values from three validations presented as bias and coefficient of variation (CV) were less than 17.2% for the lower limit of quantification and less than 7.8% for other levels.
The method showed a high recovery of approximately 95% and a low matrix effect of less than 8.7%.
DBS specimens were stable at 37°C for 2 months and at 50°C for 1 week.
The ratio of the concentration of linezolid in DBS samples to that in plasma was 1.2 (95% confidence interval [CI], 1.12 to 1.27).
Linezolid exposure calculated from concentrations DBS samples and plasma showed good agreement.